ClinicalTrials.gg
RecruitingNCT07557121Updated Nov 4, 2026

Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration

A Phase 2 interventional study of AIV007 and EYLEA® (aflibercept) Injection 2 mg (0.05mL) in Neovascular (Wet) Age-Related Macular Degeneration, sponsored by AiViva BioPharma, Inc.. Recruiting at 2 sites in United States. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by AiViva BioPharma, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 4, 2026Now RecruitingFirst site in United States+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Planned enrollment
306th of 491
35 · median 55
Started
2026
with 27 others
Phase 2
138 of 645
14 open now
Primary completion
2027-06
later than 51 of 124 live
Registered
631st of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 306th largest by planned enrollment of the 491 interventional ones that give a count, is one of 28 that started in 2026, is one of 138 in phase 2, reaches primary completion later than 51 of the 124 other live ones, and was the 631st registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

78 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to evaluate whether AIV007 provides benefits to patients with neovascular age-related macular degeneration in improving vision and that it has an acceptable safety profile.

Participants will receive either a periocular injection of AIV007 or intravitreal injection of Eylea (control arm) to the study eye and return to the clinic monthly for safety and efficacy observations and/or continued treatment. Participants may receive additional treatment(s) if they meet specified criteria.

Read the detailed description

This study will have 2 parts. In Part 1, participants will randomized to receive either AIV007 (6 or 8 mg) or standard of care in a masked fashion and followed for 6 months. The main questions to be answered are:

  1. Does AIV007 have an acceptable safety profile?
  2. Does AIV007 maintain or improve best corrected visual acuity?
  3. Does AIV007 sustain or decrease central subfield thickness?
  4. Does AIV007 provide a long duration of effect greater than or equal to 5 months? In Part 2, eligible participants will receive a second injection of AIV007 in an open-labeled design to assess safety and efficacy of repeat doses.
03

Conditions studied

  • Neovascular (Wet) Age-Related Macular Degeneration

Keywords

  • wet AMD
  • anti-VEGF
  • periocular
  • Eylea
  • tyrosine kinase inhibitor
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously treated neovascular (wet) age-related macular degeneration (nAMD)
  • Responsive to prior intravitreal anti-VEGF therapy
  • Study eye at screening must have an ETDRS letter score greater than 35 (20/200 Snellen equivalent)
  • Active choroidal neovascularization lesion in the study eye secondary to nAMD.
  • Central subfield thickness in the study eye of less than or equal to 370 microns.
  • Compliance to all study protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Study eye has had previous treatment with cell therapy, brachytherapy, and/or gene therapy
  • History of uncontrolled intraocular pressure
  • Presence of any epiretinal membrane, vitreomacular traction, subfoveal atrophy (including RPE degeneration), RPE tear in the study eye
  • History of vitreoretinal surgery, corneal transplant, glaucoma surgery in the study eye or cataract surgery within 3 months before screening visit
  • History of vitreous hemorrhage within 3 months prior to screening visit in the study eye
  • A clinically significant cataract (including PSC) likely to affect trial outcomes (i.e., vision) in the study eye
  • Anterior chamber intraocular lens, aphakia, or violation of the posterior capsule in the study eye; prior Nd:YAG laser posterior capsulotomy in association with posterior intraocular lens implantation is allowed provided it occurred at least 30 days before the screening visit
  • Any active bacterial, viral, fungal or parasitic ocular or periocular infection or any history of uveitis in either eye
  • Intraretinal fluid (IRF) in the proposed study eye of less than 30 µm confirmed by the CRC following the screening visit
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Group 1: AIV007

    Drug: AIV007

  • Experimental
    Group 2: AIV007

    Drug: AIV007

  • Active comparator
    Group 3: Eylea

    Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

Interventions

06

What researchers measure

Primary outcomes

  1. Best-corrected Visual Acuity

    Mean change from baseline in best-corrected visual acuity using ETDRS Charts

    Time frame: Month 6

Secondary outcomes

  1. Durability

    Proportion of participants that did not require supplemental medication

    Time frame: Month 5

07

Study locations

2 of 2 sites recruiting
  • Macula and Vitreous Center
    Torrance, California 90503, United States
    Recruiting
  • Valley Retina Institute, P.A.
    McAllen, Texas 78503, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.

Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's planned 11 months is below that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2026
First posted
Apr 29, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Aug 23, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 4, 2026
Sites
2 sites added — first site in United States
Show 2 added (2 United States)
  • Macula and Vitreous Center · Torrance, United States
  • Valley Retina Institute, P.A. · McAllen, United States
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in United States
    Show 2 added (2 United States)
    • Macula and Vitreous Center · Torrance, United States
    • Valley Retina Institute, P.A. · McAllen, United States
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07557121
Lead sponsor
AiViva BioPharma, Inc.
Collaborators
ClinDatrix, Inc.
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
Jul 1, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Aug 23, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Darlene C. Deecher, phd
Contact
darlene@aiviva.com
2674544560
Diane DS Tang-Liu, PHD
Contact
diane@aiviva.com
7023371797

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AIV007

Start the discussion